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Abstract
Quantitative assessment of MT1- MMP cell surface- associated proteolytic activity 
remains undefined. Presently, MT1- MMP was stably expressed and a cell- based 
FRET assay developed to quantify activity toward synthetic collagen- model triple- 
helices. To estimate the importance of cell surface localization and specific structural 
domains on MT1- MMP proteolysis, activity measurements were performed using a 
series of membrane- anchored MT1- MMP mutants and compared directly with those 
of soluble MT1- MMP. MT1- MMP activity (kcat/KM) on the cell surface was 4.8- fold 
lower compared with soluble MT1- MMP, with the effect largely manifested in kcat. 
Deletion of the MT1- MMP cytoplasmic tail enhanced cell surface activity, with both 
kcat and KM values affected, while deletion of the hemopexin- like domain negatively 
impacted KM and increased kcat. Overall, cell surface localization of MT1- MMP re-
stricts substrate binding and protein- coupled motions (based on changes in both kcat 
and KM) for catalysis. Comparison of soluble and cell surface- bound MT2- MMP 
revealed 12.9- fold lower activity on the cell surface. The cell- based assay was uti-
lized for small molecule and triple- helical transition state analog MMP inhibitors, 
which were found to function similarly in solution and at the cell surface. These stud-
ies provide the first quantitative assessments of MT1- MMP activity and inhibition in 
the native cellular environment of the enzyme.
K E Y W O R D S
cell surface proteolysis, cell-based assay, collagenolysis, matrix metalloproteinase, protease inhibitor
1252 |   PAHWA et Al.
1 |  INTRODUCTION
The quantification of cell surface- associated protease activ-
ity, along with the evaluation of inhibitor potency, is often 
performed using isolated enzyme and substrate. As a result, 
the contribution of the cell surface environment to the reg-
ulation of proteolytic activity is negated. Membrane type- 1 
matrix metalloproteinase (MT1- MMP) is a member of the 
matrix metalloproteinase (MMP) gene family, multidomain 
enzymes that are characterized by an N- terminal propeptide 
domain, a zinc- coordinating active site within the catalytic 
(CAT) domain, and a C- terminal hemopexin- like (HPX) do-
main (Rowe & Weiss, 2009). However, unlike secreted mem-
bers of the MMP family, MT1- MMP is distinguished by the 
presence of a short transmembrane (TM) domain and a cyto-
plasmic tail (CT) that serve to localize the enzyme to discrete 
regions of the plasma membrane while providing access to 
the intracellular compartment (Rowe & Weiss, 2009).
Although MT1- MMP can hydrolyze a variety of sub-
strates (Pahwa, Stawikowski, & Fields, 2014), one of its 
most important functions is the serve as a pericellular, in-
terstitial collagenase that plays key roles in events ranging 
from mesenchymal stem cell differentiation and adipose tis-
sue development to carcinoma cell proliferation, invasion, 
and metastasis (Castro- Castro et al., 2016; Rowe & Weiss, 
2009; Szabova, Chrysovergis, Yamada, & Holmbeck, 2007; 
Tang et al., 2013; Zarrabi et al., 2011). MT1- MMP collage-
nolytic activity has also been implicated in facilitating sec-
ondary infections (Talmi- Frank et al., 2016). Interestingly, 
even though MT1- MMP serves as an interstitial collagenase, 
in similar fashion to several secreted MMPs (i.e., MMP- 1, 
MMP- 8, and MMP- 13), only MT1- MMP activity is critical 
for conferring cells with tissue- invasive properties (Fisher 
et al., 2009; Hotary, Allen, Punturieri, Yana, & Weiss, 2000; 
Koike, Vernon, Hamner, Sadoun, & Reed, 2002; Sabeh, Li, 
Saunders, Rowe, & Weiss, 2009; Sabeh et al., 2004; Wolf 
et al., 2007; Zhang, Matrisian, Holmbeck, Vick, & Rosenthal, 
2006). Hence, the plasma membrane environment appears to 
regulate MT1- MMP collagenolytic activity. While quantita-
tive assessments of MT1- MMP catalytic activity at the cell 
surface should clarify the potential influences and effects that 
the membrane environment elicits on catalytic activity under 
native conditions, such determinations have remained prob-
lematic (see below).
Visualization of membrane- bound, active MT1- MMP 
has been achieved by fluorescence resonance energy trans-
fer (FRET) imaging of surface- anchored sensors. An initial 
MT1- MMP sensor was created using the Cys- Pro- Lys- Glu- 
Ser- Cys- Asn- Leu- Phe- Val- Leu- Lys- Asp sequence, derived 
from the MT1- MMP cleavage site in proMMP- 2 (Ouyang 
et al., 2008). The FRET pair was an Enhanced Cyan 
Fluorescence Protein (ECFP, the fluorophore) and a Yellow 
Fluorescence Protein variant (YPet, the quencher) (Ouyang 
et al., 2008). A second generation sensor was created using 
the sequence Cys- Arg- Pro- Ala- His- Leu- Arg- Asp- Ser- Gly 
and the FRET pair mOrange2 (fluorophore) and mCherry 
(quencher), yielding a biosensor that was largely insensitive 
to MMP- 2- or MMP- 9- dependent hydrolysis (Ouyang et al., 
2010). To improve the biosensor’s selectivity, a pentapeptide 
library was screened, and the sensor CyPet- Ser- Leu- Ala- Pro- 
Leu- Gly- Leu- Gln- Arg- Arg- YPet (where Cyan Fluorescence 
Protein variant (CyPet) was the fluorophore) was found to be 
more selective for MT1- MMP compared with other MMPs, 
with the exception of MMP- 9 (Jabaiah & Daugherty, 2011). 
A further optimized MT- MMP probe was developed based 
on the sequence AHLR (Cys- Arg- Pro- Ala- His- Leu- Arg- Asp- 
Ser- Gly) with Gly- Gly- Ser- Gly- Gly- Thr linkers flanking each 
side of the sequence and ECFP and YPet as a FRET pair (Lu 
et al., 2013). MT1- MMP activity was favored over MMP- 2 
and MMP- 9 as well as the membrane- anchored MMPs, MT2- 
MMP, and MT3- MMP. However, the insufficient selectivity 
of sensors that are based on short linear peptides did not 
allow for the precise quantification of cellular MT1- MMP 
activity under native conditions, and the recorded changes in 
fluorescence were not sufficiently robust for routine analysis.
A more recent biosensor for MT1- MMP was created 
using a separate donor and acceptor that assembled in situ 
(Limsakul et al., 2018). Specifically, a monobody (PEbody) 
was developed to bind to R- phycoerythrin (R- PE) dye. The 
PEbody was fused with ECFP and also inserted into the cell 
membrane. An MT1- MMP labile sequence (Cys- Arg- Pro- 
Ala- His- Leu- Arg- Asp- Ser- Gly) was incorporated between 
the ECFP and the PEbody. MT1- MMP hydrolysis resulted 
in a decrease in FRET. Images were reported to be clearer 
than for the ECFP/YPet sensor (Ouyang et al., 2008). The 
ECFP- PEbody/R- PE biosensor was used to study the local-
ization and mobility of MT1- MMP, but not to quantify activ-
ity. Interestingly, this study found that MT1- MMP mobility 
was restricted by inhibition partners (Limsakul et al., 2018).
Imaging of MT1- MMP activity on the surface of human 
mesenchymal stem cells was achieved using a three- 
dimensional PEG- hydrogel that incorporated the MMP 
substrate Dabcyl- Gly- Gly- Pro- Gln- Gly- Ile- Trp- Gly- Gln- 
Lys(fluorescein)- Ahx- Cys (Leight, Alge, Maier, & Anseth, 
2013). The relative change in fluorescence was quantified, 
but no kinetic parameters were reported. The sequence used 
was not specific for MT1- MMP.
For the purpose of analyzing cell surface proteolytic en-
zymes, one would ideally utilize substrates that correspond to 
the most prominent activity of a targeted protease. As such, 
synthetic triple- helical peptide (THP) substrates that model 
interstitial (types I- III) collagen have been developed for con-
venient, continuous activity- monitoring assays. FRET THPs 
(fTHPs) have typically used (7- methoxycoumarin- 4- yl)- acetyl 
(Mca) as a fluorophore that, in turn, is efficiently quenched 
by 2,4- dinitrophenyl (Dnp) moieties (Knight, Willenbrock, & 
   | 1253PAHWA et Al.
Murphy, 1992; Nagase, Fields, & Fields, 1994). These fTHPs 
have been employed to discriminate MMP family members 
in kinetic assays in vitro, as well as in transfer FRET assays 
in cultured cells. Additionally, we have described an in situ 
(non- transfer) MMP cell- based assay using FRET peptide 
substrates (Giricz, Lauer, & Fields, 2011).
In the present study, MT1- MMP was stably expressed 
in cells and a cell- based FRET assay used to quantify cell 
surface- associated protease activity and its kinetic param-
eters. To determine the effect of the cell surface and the 
individual MT1- MMP domains on catalysis, activity com-
parisons were made using soluble (i.e., transmembrane- 
deleted) MT1- MMP and surface- bound MT1- MMP mutants. 
Given recent, and often contradictory, reports regarding the 
role of the MT1- MMP CT, CAT domain, and HPX domain 
in regulating proteolytic activity (Cao et al., 2008; Itoh et al., 
2001, 2006; Li, Ota, Yana, Sabeh, & Weiss, 2008; Sabeh 
et al., 2009; Tam, Moore, Butler, & Overall, 2004; Weaver 
et al., 2014; Yu et al., 2012), we also assessed the enzymatic 
properties of MT1- MMP following (a) deletion of the CT 
[MT1- MMP(ΔCT)], to determine if a lack of enzyme in-
ternalization, partitioning into lipid rafts, and/or CT post- 
translation modification modulates activity, (b) deletion of 
the HPX domain [MT1- MMP(ΔHPX)], to determine the role 
of the HPX domain in cell surface collagenolysis, and (c) re-
placement of the MT1- MMP CAT domain with the MMP- 1 
CAT domain [MT1- MMP(MMP- 1 CAT)], to determine if the 
MT1- MMP CAT domain is optimal for cell surface collag-
enolysis (Figure 1). Activity of the soluble and cell- bound 
forms of MT2- MMP was evaluated for comparison to MT1- 
MMP. Finally, the effect of two distinct classes of inhibitors 
on cell surface MT1- MMP proteolysis was examined.
2 |  EXPERIMENTAL SECTION
2.1 | Methods and materials
Cell culture reagents were obtained from Invitrogen un-
less otherwise stated. Standard chemicals were of analyti-
cal or molecular biology grade and purchased from Fisher 
Scientific. Antibodies were purchased from EMD Millipore 
and Pierce. The triple- helical substrate fTHP- 9 [(Gly- Pro- 
Hyp)5- Gly- Pro- Lys(Mca)- Gly- Pro- Gln- Gly~Cys(Mob)- 
Arg- Gly- Gln- Lys(Dnp)- Gly- Val- Arg- (Gly- Pro- Hyp)5- NH2] 
and the triple- helical peptide inhibitor GlyΨ{PO2H- CH2}
Ile- Tyr THPI [(Gly- Pro- Hyp)4- Gly- mep- Flp- Gly- Pro- 
Gln- [GlyΨ(PO2H- CH2)Ile]- Tyr- Phe- Gln- Arg- Gly- Val- 
Arg- Gly- mep- Flp- (Gly- Pro- Hyp)4- Tyr- NH2, where 
mep = 4- methylproline and Flp = 4- fluoroproline] were 
synthesized in house using methods described previously 
(Bhowmick & Fields, 2012; Bhowmick et al., 2017; Lauer- 
Fields et al., 2007; Minond, Lauer- Fields, Nagase, & Fields, 
2004; Minond et al., 2006). Marimastat, a nonselective in-
hibitor of MMPs (Beckett & Whittaker, 1998; Rasmussen & 
McCann, 1997), was purchased from Sigma. Tissue inhibitor 
of metalloproteinase 2 (TIMP- 2) was obtained from Abcam 
(catalog # ab39314).
2.2 | Cell culture and transfection
COS- 1 cells (CRL- 1650) were obtained from ATCC. Human 
MCF- 7 breast carcinoma cells that express low levels of 
MT1- MMP and negligible levels of MMP- 8 were cultured 
as described previously in Dulbecco’s modified Eagle’s me-
dium (DMEM) with 10% fetal calf serum (FCS) (Köhrmann, 
Kammerer, Kapp, Dietl, & Anacker, 2009; Rozanov et al., 
2001). The plasmid construct for producing human solu-
ble MT1- MMP (MT1- MMP without its TM domain and 
CT, designated sMT1- MMP) was described previously 
(Cao et al., 2004; Pei & Weiss, 1996). The pCDNA 3.1 
plasmids containing human wild- type MT1- MMP (WT- 
MT1- MMP), MT1- MMP with its cytoplasmic tail deleted 
[MT1- MMP(ΔCT)], MT1- MMP with the HPX domain de-
leted [MT1- MMP(ΔHPX)], and MT1- MMP in which the 
entire CAT domain was replaced with the CAT domain of 
human MMP- 1 [MT1- MMP(MMP- 1 CAT)] have also been 
described (Li et al., 2008; Sabeh et al., 2009). The MT1- 
MMP(MMP- 1 CAT) construct was composed of MMP- 1 
Met1 to Tyr260 with the Gly- Leu- Ser- Ser- Aal- Arg- Asn- Arg- 
Gln- Lys- Arg sequence inserted between the Pro and CAT 
domains, and MT1- MMP Gly284 to Val582 (Li et al., 2008; 
Pei & Weiss, 1995) The inserted sequence allows for furin 
F I G U R E  1  Schematic illustration 
of MT1- MMP constructs. Domains of 
MT1- MMP are propeptide (Pro) in green, 
catalytic (CAT) in blue, hinge (Hinge) 
in purple, hemopexin- like (HPX) in 
burgundy, transmembrane (TM) in blue, 
and cytoplasmic tail (CT) in red. Blue 
prodomain and orange CAT domain 
represent MMP- 1 [Colour figure can be 
viewed at wileyonlinelibrary.com]
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activation of the resulting chimera (Pei & Weiss, 1995). All 
pCDNA 3.1 plasmids containing WT- MT1- MMP and mu-
tants were used for stable transfection of MCF- 7 cells. Control 
cells were transfected with the original pCDNA3.1 plasmid. 
MCF- 7 cells were stably transfected using X- tremeGENE 
9 Reagent (Roche) followed by isolation of single colonies 
after 4–6 weeks of geneticin selection. Transfected cells were 
routinely grown in selective medium (DMEM supplemented 
with 10% FCS and 0.55 mg/ml geneticin).
The MT2- MMP construct (Met1 to Val669 with an HA 
tag (human influenza hemagglutinin residues 98–106) in the 
linker 2 region (between Glu584 and Pro585) has been de-
scribed previously (Hotary et al., 2000; Ota, Li, Hu, & Weiss, 
2009).
2.3 | Soluble protein 
production and detection
To generate soluble MT1- MMP, sMT1- MMP was tran-
siently transfected in COS- 1 cells. Transfected COS- 1 cells 
were cultured for 56 hr in serum- free OptiMEM. Conditioned 
medium was collected, concentrated 20- fold, and desalted 
using Ultracel®- 30K centrifugal filters (Millipore, catalog 
# UFC903024). Concentrated samples were pooled and 
dialyzed against TSB buffer (50 mM Tris, 50 mM NaCl, 
10 mM CaCl2, 0.05% Brij- 35, pH 7.5) using the Slide- A- 
Lyzer Dialysis Cassette 20K (Thermo Scientific, product # 
66102) overnight at 4°C. Protein samples were resolved by 
reducing 12% SDS- polyacrylamide gel electrophoresis and 
transferred onto a PVDF membrane. The membrane was 
blocked with 5% non- fat dry milk in PBS plus 0.1% Tween 
(PBST) for 1 hr at ambient temperature and then probed 
with an anti- MT1- MMP HPX domain mAb (Millipore, cata-
log # MAB3317) for 16 hr at 4°C. After extensive washing 
with PBST, the membrane was reprobed using goat anti- 
mouse IgG conjugated with horseradish peroxidase (HRP) 
(Millipore, catalog # AP124P) in PBST for 1 hr at ambient 
temperature. The blot was developed in a SuperSignal® West 
Pico Chemiluminescent Substrate (Thermo Scientific).
To generate soluble MT2- MMP, MT2- MMP Met1 to 
Asn625 with an N- terminal His tag was stably transfected 
in MCF- 7 cells as described (Hotary et al., 2000; Ota et al., 
2009). FBS free media was collected, concentrated, and buf-
fer exchanged to TSB buffer. The protein was then isolated 
using His trap resin, eluted with 100 mM imidazole, and dia-
lyzed overnight in TSB buffer.
MT1- MMP and MT2- MMP were activated by incubation 
of the proMT- MMP in TSB buffer with 0.1 μg/ml of rhTryp-
sin- 3 for 1 hr (proMT1- MMP) or 2 hr (proMT2- MMP) at 
37°C (Fu et al., 2013). After MT- MMP activation, remaining 
trypsin- 3 activity was quenched by addition of 1 mM AEBSF 
(R&D Systems) and incubation for 15 min at room tempera-
ture. Immediately after activation, the enzyme was diluted in 
cold TSB buffer. Enzyme aliquots were kept on wet ice and 
used the same day.
2.4 | Cell extract preparation from stably 
transfected cells
Stably transfected MCF- 7 cells with WT- MT1- MMP or its 
mutants were cultured in selective medium. For Western blot 
analysis, the cultured cells were directly lysed on the 6- well 
tissue culture plates using 200 μl/well of RIPA buffer with 
protease inhibitor cocktail (Sigma, catalog # P8340). A tis-
sue culture cell scraper was applied to each well and cell 
lysates were collected with a pipette and kept on ice. After 
centrifugation, the protein content of the supernatants was 
quantified by the Pierce BCA Protein Assay Kit (Thermo 
Scientific) carried out in triplicate in wells of a 96- well plate. 
MT1- MMP production was confirmed by Western blot as de-
scribed above using mAbs against either the MT1- MMP CAT 
domain or the MT1- MMP hinge domain (Millipore, catalog 
# ab6005 and ab6004, respectively) and goat anti- rabbit IgG- 
HRP (Genescript, catalog # A00098) as a secondary anti-
body. β- actin mAb BA2R (Pierce, catalog #MA5- 15739) was 
used as a loading control.
2.5 | Soluble enzyme assay
Substrate stock solutions were prepared at various concentra-
tions in TSB buffer containing 0.5% DMSO. MT1- MMP and 
MT2- MMP assays were conducted in TSB buffer by incubat-
ing a range of substrate concentrations (0.05–30 μM) with 7 
and 9 nM enzyme, respectively, at 37°C. Fluorescence was 
measured on a multiwell plate fluorimeter (Biotek Synergy 
H1) using λexcitation = 324 nm and λemission = 405 nm. The 
same kinetic assay was also run in OptiMEM media as op-
posed to TSB buffer and showed no deviation in the kinetic 
parameters (data not shown). Rates of hydrolysis were ob-
tained from plots of fluorescence versus time, using data 
points from the linear portion of the hydrolysis curve alone. 
The slope from these plots was divided by the fluorescence 
change corresponding to complete hydrolysis and then mul-
tiplied by the substrate concentration to obtain rates of hy-
drolysis in units of μM/s. The relationship between the rate 
of hydrolysis and substrate concentration for the MT- MMP/
fTHP- 9 pair for which individual kinetic parameters were de-
termined was found to follow the Michaelis–Menten model. 
Kinetic parameters were evaluated by Lineweaver–Burk, 
Eadie–Hofstee, and Hanes–Woolf analyses. Data were ad-
ditionally analyzed using nonlinear regression, one- site hy-
perbolic binding model with GraphPad Prism 5 software. 
All the values reported are mean ± SD (n = 3). MMP sub-
strate cleavage sites were established by MALDI- TOF MS 
and found to be consistent with previously published data 
(Minond et al., 2006).
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2.6 | Cell surface-bound enzyme assay
The in situ enzyme assays were run in wells of a 384- well 
tissue  culture treated opaque microplate (Greiner Bio- One, 
catalog # 781080). To minimize plate- based differences, the 
same plate type was used for both soluble and cell surface-
bound enzyme assays. Stably transfected cells with passage 
number 3–8 were used in the assay. Cells (6 × 103/well) were 
seeded in OptiMEM Medium and then incubated overnight at 
37°C in a CO2 incubator before the assay. The assays were 
carried out in serum- free OptiMEM with fTHP- 9 dissolved 
in the same media with 0.5% DMSO in a total volume of 
60 μl. Proteolytic activity was determined by calculating the 
percentage increase in fluorescence compared to the back-
ground signal provided by the corresponding dilution of the 
substrates with no cells using a multiwell plate fluorimeter (as 
described previously). Estimation of the active MT1- MMP 
and MT2- MMP enzyme levels was performed by TIMP- 2 
titration (Minond et al., 2006). Cells (6 × 103/well) were in-
cubated with a 1.5–200 nM concentration range of TIMP- 2. 
By accounting for active protease concentrations, enzyme 
kinetics will not be affected by different levels of protein ex-
pression. The rate of hydrolysis was calculated as described 
above. All the values reported are mean ± SD (n = 3).
2.7 | Inhibition assay
Stock solutions of GlyΨ{PO2H- CH2}Ile- Tyr THPI, marimas-
tat, and fTHP- 9 were prepared in OptiMEM media with 0.5% 
DMSO. Inhibitors were prepared over a 1 nM to 5 μM con-
centration range. Cells (6 × 103/well) were seeded in wells 
of a 384- well plate. Inhibitors were added to the wells and 
incubation proceeded for 45 min at 37°C. After incubation, 
15 μM of fTHP- 9 was added to the wells and fluorescence 
was recorded for 30 min and an increase in relative fluores-
cence units (RFU) determined as described above. IC50 val-
ues were determined using graphpad prism 5 software.
3 |  RESULTS
Soluble MT1- MMP (sMT1- MMP; Figure 1) was isolated 
from the media of COS- 1 cells transiently transfected with 
the sMT1- MMP cDNA. As expected, sMT1- MMP was se-
creted as both proenzyme (65 kDa) and activated (57 kDa) 
forms (Figure 2) (D’ortho et al., 1997; Pei & Weiss, 1996; 
Roderfeld, Büttner, Bartnik, & Tschesche, 2000). The pro-
enzyme form of sMT1- MMP was then activated using 
rhTrypsin- 3 for 1 hr, followed by trypsin- 3 inactivation by 
addition of AEBSF. Trypsin activation of proMT1- MMP gen-
erates a single product at the N- terminus starting with Tyr112 
(Will, Atkinson, Butler, Smith, & Murphy, 1996). This cleav-
age site was identical to that observed following the cellular 
activation of proMT1- MMP by the trans- Golgi- associated 
serine proteinase furin (Pei & Weiss, 1996). Following 
TIMP- 2 titration, 160 nM of the active enzyme was detected 
in the sMT1- MMP samples (40% of total protein). Initially, 
the single- stranded modified Knight substrate [Mca- Lys- Pro- 
Leu- Gly- Leu- Lys(Dnp)- Ala- Arg- NH2] served as a control to 
assess activity. Hydrolysis of the substrate by sMT1- MMP 
proceeded with kcat/KM = 38,560 M−1 s−1, KM = 21.3 μM, 
and kcat = 0.82/s. The recorded kcat/KM value was 2.6–3.7- 
fold higher compared to prior kcat/KM values obtained with 
other sMT1- MMP samples (Tyr112- Glu523, expressed in 
Pichia pastoris) and similar FRET substrates (Hurst et al., 
2004).
Kinetic parameters (KM, kcat, and kcat/KM) were next de-
termined for hydrolysis of the triple- helical substrate fTHP- 9 
by sMT1- MMP using a 384- well plate format. For sMT1- 
MMP hydrolysis of fTHP- 9, kcat/KM = 45,130 M−1 s−1, 
KM = 18.6 μM, and kcat = 0.9/s were recorded. To quantify 
the catalytic activity of cellular MT1- MMP, MCF- 7 cells 
that express little, if any, endogenous MT1- MMP, were engi-
neered to stably express the wild- type proteinase. High levels 
of MT1- MMP were confirmed in transfected cells relative 
to mock- transfected cells as determined by Western blotting 
(Figure 3), wherein 63- and 42- kDa protein bands were de-
tected, corresponding to the active enzyme and its autocatalyt-
ically generated inactive fragment, respectively (Osenkowski, 
Toth, & Fridman, 2004; Schröder, Hoffman, Hecker, Korff, 
F I G U R E  2  Protein expression, production, and purification 
of soluble MT1- MMP (sMT1- MMP). (a) SDS- PAGE analysis of 
purified protein. Protein was run on 12% SDS- PAGE gel under 
reducing conditions and (b) analyzed by Western blot with anti- MT1- 
MMP HPX domain mAb. Gel and Western blot analyses showed the 
proenzyme (65 kDa) and active (57 kDa) forms of sMT1- MMP
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& Ludwig, 2013). The levels of MT1- MMP stably ex-
pressed in the MCF- 7 cells were similar to those observed 
for MDA- MB- 231 cells (data not shown), the latter of which 
endogenously expresses MT1- MMP (Lafleur et al., 2005). 
Parameters such as optimal cell number and suitable media 
for the assay were subsequently established. When the cell 
number was varied between 1.25 × 103 and 1.0 × 104 MT1- 
MMP transfectants/well and activity measured using fTHP- 9, 
activity peaked at 5–6 × 103 cells/well (data not shown). For 
estimation of the levels of active enzyme mobilized to the 
cell surface, the hydrolytic activity of 6 × 103 cells/well was 
titrated with increasing concentrations of TIMP- 2 (Zucker 
et al., 1998). Under these conditions, WT- MT1- MMP trans-
fectants were estimated to express ~2.28 nM active proteinase, 
whereas control cells expressed ~0.96 nM of active metallo-
proteinase activity, likely representing endogenous proteases 
produced by MCF- 7 cells (e.g., MT2- MT6- MMPs) that are 
also inhibited by TIMP- 2 (Table 1). With the endogenous 
activity treated as background, stable transfection of MCF- 7 
cells resulted in the expression of approximately 7.95 × 106 
active MT1- MMP molecules/cell ((1.32 × 10−9 moles/L) 
× (60 × 10−6 L) × (6.022 × 1023 molecules/mole))/(6 × 103 
cells)). This number is comparable to those reported in prior 
studies using imaging approaches. For example, using the 
MP- 3653 reporter (a PEG- liposome possessing a hydroxamic 
acid for MMP targeting and carboxyfluorescein for imaging) 
for quantification, MT1- MMP transfection of MCF- 7 cells 
resulted in ~1.1 × 106 molecules/cell (Remacle et al., 2013). 
MT1- MMP concentrations on uterus carcinoma SiHa cell 
surfaces were determined using gold nanoclusters containing 
MT1- AF7p (sequence Cys- Cys- Tyr- His- Trp- Lys- His- Leu- 
His- Asn- Thr- Lys- Thr- Phe- Leu) (Zhang et al., 2018), where 
MT1- AF7p binds to the MT1- MMP “MT- loop” region. 
MT1- MMP concentration was 5.24–12.47 × 10−18 moles per 
cell (3.16–7.51 × 106 MT1- MMP molecules/cell).
Kinetic analyses demonstrated that WT- MT1- MMP dis-
played a KM = 15.1 μM (Table 2), a value similar to that ob-
served with sMT1- MMP (i.e., 18.6 μM). Interestingly, the 
kcat/KM value for the membrane- tethered enzyme was 4.8- 
fold lower relative to that determined for the soluble enzyme 
(Table 2), based primarily on a kcat for WT- MT1- MMP that 
was decreased sixfold relative to that of sMT1- MMP. These 
results suggest that, under similar experimental conditions, 
the membrane- anchored enzyme is less efficient collageno-
lytically compared with the soluble protease. As the effect 
is primarily a function of kcat, membrane- bound MT1- MMP 
may have limited conformational flexibility, a parameter that 
restricts the coupled motions required for catalysis (Watt, 
Shimada, Kovrigin, & Loria, 2007).
To identify putative effects of the individual MT1- MMP 
domains on catalytic activity, MT1- MMP mutants (MT1- 
MMP(ΔCT), MT1- MMP(ΔHPX), and MT1- MMP(MMP- 1 
CAT)) (see Figure 1) were each stably expressed in MCF- 7 
cells and the active protease levels quantified by TIMP- 2 ti-
tration. MT1- MMP(ΔCT) transfected cells displayed a 2.0- 
fold increase of the active enzyme at the cell surface relative 
to the wild- type construct (Table 1). These results are consis-
tent with prior studies demonstrating that deletion of the CT 
delays endocytosis and consequently allows the mutant en-
zyme to accumulate at the cell surface, likely in the lipid raft 
compartment (Jiang et al., 2001; Remacle, Murphy, & Roghi, 
2003), but contradict reports suggesting that the MT1- MMP 
T A B L E  1  TIMP- 2 titration for active enzyme evaluation
MT- MMP variant
MT- MMP (nM) 
per well
Mock cells 0.96 ± 0.09a
WT- MT1- MMP 2.28 ± 0.18a
MT1- MMP(ΔCT) 4.46 ± 0.24a
MT1- MMP(ΔHPX) 3.38 ± 0.13a
MT1- MMP(MMP- 1 CAT) 3.32 ± 0.15a
WT- MT2- MMP 4.61 ± 0.23a
Note. Enzyme concentrations were determined as described in Section 2.6.
aAlthough the determined cell surface enzyme concentrations are only ~2–4 times 
greater than the Ki value for the inhibitor (1.4 nM; Zucker et al., 1998), they are 
comparable to that determined by a different method for MT1- MMP expressed in 
the same cell line (see Results; Remacle et al., 2013). 
MT- MMP variant KM (μM) kcat/KM (M−1 s−1) kcat (s−1)
sMT1- MMP 18.6 ± 1.4 45,130 ± 6,641** 0.84
WT- MT1- MMP 15.1 ± 2.2 9,315 ± 3,262* 0.14
MT1- MMP(ΔCT) 11.2 ± 0.79 19,060 ± 1,760** 0.21
MT1- MMP(ΔHPX) 23.4 ± 2.9 8,430 ± 608** 0.2
MT1- MMP(MMP- 1 CAT) 36.8 ± 4.4 2,237 ± 367** 0.08
sMT2- MMP 2.41 ± 1.0 43,180 ± 51.1 0.1 ± 0.032
WT- MT2- MMP 6.95 ± 0.81 3,336 ± 51.1 0.03 ± 0.003
Note. Kinetic parameters were determined as described in Sections 2.5 and 2.6. Results are presented as 
mean ± SD, as indicated. Statistical comparisons were performed with one- way analysis of variance (ANOVA) 
using sigmaplot v12.5 (SPSS, Inc., Chicago, IL). Statistical significance was defined as *p < 0.05 and 
**p < 0.001.
T A B L E  2  Kinetic parameters for 
fTHP- 9 hydrolysis by secreted and 
membrane- anchored MT- MMP
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CT plays a required role in regulating proteolytic activity at 
the cell surface (Uekita, Itoh, Yana, Ohno, & Seiki, 2001; 
Yu et al., 2012). MCF- 7 cells expressing MT1- MMP(ΔHPX) 
also displayed higher levels of bound TIMP- 2 when com-
pared to cells expressing WT- MT1- MMP (Table 1), likely 
due to decreased MT1- MMP endocytosis, as the HPX do-
main can regulate MT1- MMP internalization as a function of 
its interactions with the tetraspanins (Schröder et al., 2013). 
Interestingly, cells expressing MT1- MMP(MMP- 1 CAT) also 
had higher levels of the active enzyme compared with WT- 
MT1- MMP cells (Table 1). This may be due to the reduced 
ability of the MMP- 1 CAT domain to support the autocata-
lytic cleavage of the chimera from the cell surface compared 
with the native MT1- MMP construct (see Figure 3) (Li et al., 
2008; Osenkowski et al., 2004).
The active enzyme concentrations at the cell surface 
differed (Table 1), while Western blotting showed simi-
lar levels of protein production (Figure 3). However, the 
Western blots were for cell lysates, and thus included both 
cell  surface-bound and internalized enzyme. Biotinylation 
of cell surface proteins (Schröder et al., 2013) followed by 
Western blot analysis revealed higher levels of cell surface 
MT1- MMP(ΔCT) protein compared with WT- MT1- MMP 
(data not shown).
The kinetic parameters were next determined for fTHP- 9 
hydrolysis by each of the MT1- MMP mutants (Table 2). 
Deletion of the CT resulted in a small decrease in the KM 
compared to the wild- type enzyme, whereas kcat was substan-
tially increased. Hence, the MT1- MMP CT does not play a 
required role in controlling the enzyme’s catalytic activity. 
By contrast, in the absence of the HPX domain, the KM value 
increased compared with the wild- type enzyme, supporting 
an important role for this domain in the binding to the col-
lagen triple- helix (D’ortho et al., 1997; Li et al., 2008; Tam 
et al., 2004), while the kcat value increased significantly. 
Nevertheless, these results demonstrate that the HPX do-
main, while capable of modulating MT1- MMP activity, is 
not required for the expression of collagenolytic activity (Li 
et al., 2008). When the CAT domain of MT1- MMP was re-
placed with that of MMP- 1, fTHP- 9 hydrolytic activity was 
likewise retained although with a twofold increase in KM and 
a 50% decrease in kcat (Table 2). Hence, though the structure 
of the chimeric enzyme may be negatively impacted by po-
tential domain clashes between MT1- MMP and MMP- 1, the 
membrane- anchored construct retains significant enzymatic 
activity against the triple- helical substrate, highlighting the 
fact that cell surface collagenolytic activity per se is not a 
unique characteristic of the MT1- MMP CAT domain (Li 
et al., 2008; Sabeh et al., 2009).
F I G U R E  3  Western blotting of transfected MCF-7 cells. MCF-7 
cells stably transfected with the original pcDNA3.1 plasmid (Control) 
or WT-MT1-MMP, MT1-MMP(∆CT), MT1-MMP(∆HPX), or MT1-
MMP(MMP-1 CAT) were lysed and samples identified by Western 
blotting with anti-MT1-MMP (a) CAT domain mAb or (b) hinge 
domain mAb. Western blot analysis showed the active (63 kDa) and 
autodegraded (42 kDa) forms of WT-MT1-MMP or MT1-MMP(ΔCT), 
as well as the active forms of MT1-MMP(MMP-1 CAT) (56 kDa) or 
MT1-MMP(ΔHPX) (42 kDa). In the case of MT1-MMP(ΔHPX), the 
protein observed at 63 kDa is natural production of WT-MT1-MMP by 
MCF-7 cells. The lowest MW degradation product in the WT-MT1-
MMP and MT1-MMP(ΔCT) samples (~18 kDa) probably corresponds 
to the autocatalytically generated Tyr112-Ala255 MT1-MMP, which 
is inactive and does not bind TIMP-2 (Toth et al., 2002). The other 
degradation products observed in the MT1-MMP(ΔCT) sample 
(MW ~31–35 kDa) may be related to non-autocatalytic processing 
within the HPX domain (Toth et al., 2002). These fragments would 
be released from the cell surface (Osenkowski et al., 2004). Results 
shown are representative of three or more experiments performed. As 
observed previously, WT-MT1-MMP, MT1-MMP(ΔCT), and MT1-
MMP(MMP-1 CAT) exhibit similar mobility in Western blot analysis 
(Cao et al., 2004; Li et al., 2008). The loading control was β-actin
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To examine the effects of the cell surface on another 
MMP, the activity of MT2- MMP in solution and in cells was 
compared. MT2- MMP was found previously to catalyze the 
hydrolysis of fTHP- 9 (Minond et al., 2006). In this case, sol-
uble MT2- MMP was found to have much greater activity to-
ward fTHP- 9 than cell surface- bound MT2- MMP (Table 2).
Finally, to compare the efficacy of synthetic inhibitors 
toward soluble versus membrane- bound MT1- MMP, we uti-
lized two well- characterized MMP inhibitors. Marimastat is 
a small molecule hydroxamate that chelates the active site 
Zn2+ (Whittaker, Floyd, Brown, & Gearing, 1999), whereas 
GlyΨ{PO2H- CH2}Ile- Tyr THPI is a transition state (phosph-
inate) analog that interacts with both the active site and sec-
ondary binding sites (exosites) of MT1- MMP (Lauer- Fields 
et al., 2009). Marimastat exhibited an IC50 = 19 ± 3 nM for 
the soluble enzyme and an IC50 = 36 ± 8 nM for membrane- 
bound WT- MT1- MMP as determined in the cell- based assay. 
GlyΨ{PO2H- CH2}Ile- Tyr THPI had an IC50 = 20 ± 4 nM 
with the soluble enzyme and an IC50 = 36 ± 6 nM with the 
membrane- bound WT- MT1- MMP. Thus, the potencies of 
both inhibitors were decreased ~twofold when comparing the 
cell surface-bound to the soluble form of MT1- MMP.
4 |  DISCUSSION
Evaluating enzyme kinetics of proteinases tethered to the 
cell surface relative to those of soluble proteinases can pro-
vide insight into the roles of the membrane microenviron-
ment in regulating catalytic activity (Black et al., 2003). 
To this end, we used a series of membrane- anchored and 
soluble forms of MT1- MMP to define the role of the cell 
surface and individual protease domains on MT1- MMP 
activity and catalytic efficiency. Enzyme activity was 
measured via a cell- compatible FRET assay, whereby an 
increase in fluorescence upon hydrolysis allowed for the 
rapid kinetic evaluation of the MT1- MMP proteolytic ac-
tivity in an intact cell system. In the past, THP substrate 
models of triple- helical collagen have allowed for signifi-
cant advancements in the characterization of collagenoly-
sis (Arnold et al., 2011; Bertini et al., 2012; Lauer- Fields 
et al., 2009; Manka et al., 2012). The use of fTHP- 9 is based 
on its high selectivity for MT1- MMP and MMP- 8 com-
pared with other collagenolytic MMPs as a consequence of 
the presence of Cys(Mob) in the P1′ subsite (Minond et al., 
2006). Structural analyses of MMP S1′ binding pockets in-
dicated that MT1- MMP can better accommodate large hy-
drophobic residues compared with MMP- 1, based on the 
Arg214 residue in MMP- 1 versus Leu in MT1- MMP (Bode 
et al., 1999; Maskos, 2005). MT1- MMP is thus consid-
ered to have a deep, tunnel- like S1′ pocket, while MMP- 1 
has a shallow S1′ pocket (de Oliveira, Zissen, Mongon, & 
McCammon, 2007). Indeed, fTHP- 9 was hydrolyzed at a 
rate 36- fold higher by MT1- MMP compared with MMP- 1 
(Minond et al., 2006). Further, in contrast to MT1- MMP, 
fTHP- 9 is a very inefficient substrate for MMP- 2 and 
MMP- 9 (Minond et al., 2006). As MMP- 2 and MMP- 9 
possess an intermediate- sized S1′ pocket (de Oliveira et al., 
2007), these proteinases may not efficiently accommodate 
the Cys(Mob) side chain. Based on these advantageous 
parameters, fTHP- 9 was used as a preferred substrate to 
quantify the collagenolytic activity of various MT1- MMP 
forms in our current study.
Soluble MT1- MMP exhibited a higher activity than 
cell surface-bound proteinase (Table 2), an expected result 
given that tethering of the proteinase to the cell surface 
restricts its diffusion to the soluble substrate (Itoh et al., 
2006). However, the difference was manifested almost en-
tirely in kcat, suggesting that the cell surface modulates the 
coupled motions for catalysis (Watt et al., 2007). Protein 
motions and catalytic activity are likely linked in collag-
enolytic MMPs with prior studies supporting the exis-
tence of multiple coupled conformational states in MMP- 1 
(Bertini et al., 2012; Cerofolini et al., 2013; Lauer- Fields 
et al., 2009).
Soluble MT2- MMP was found to process fTHP- 9 at a 
similar kcat/KM value as MT1- MMP (Table 2). This differs 
from the collagenolytic activities of these enzymes, where 
soluble MT1- MMP has much greater activity toward type I 
collagen than MT2- MMP (Morrison & Overall, 2006). The 
difference in activity between soluble and cell surface-bound 
MT2- MMP was greater than the difference for these two 
MT1- MMP constructs (Table 2). In this case, the difference 
between the MT2- MMP constructs was manifested in both 
kcat and KM. The results suggest that MT2- MMP is a far less 
efficient collagenolytic enzyme than MT1- MMP when bound 
to the cell surface. This result is consistent with observations 
for type I collagen invasion by COS- 1 cells transiently trans-
fected with MT1- MMP or MT2- MMP (Hotary et al., 2000).
The MT1- MMP constructs evaluated herein allowed 
for the examination of the roles of several individual do-
mains on the overall collagenolytic activity of MT1- MMP. 
It has been shown previously that MT1- MMP undergoes 
clathrin- dependent internalization mediated via the CT 
(Itoh & Seiki, 2006; Lehti, Lohi, Juntunen, Pei, & Keski- 
Oja, 2002; Lehti, Valtanen, Wickstrom, Lohi, & Keski- Oja, 
2000). However, the MT1- MMP CT has also been shown 
to interact with intracellular binding partners, such as the 
FAK- p130Cas complex, and to undergo post- translational 
modifications, including Tyr and Thr phosphorylation, Lys 
ubiquitination, and Cys palmitoylation (Anilkumar et al., 
2005; Eisenach, de Sampaio, Murphy, & Roghi, 2012; 
Moss, Wu, Liu, Munshi, & Stack, 2009; Nyalendo et al., 
2007; Wang & McNiven, 2012). While the CT has been 
reported to negatively regulate cell- mediated MT1- MMP 
proteolytic activity (Uekita et al., 2001; Yu et al., 2012), 
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this domain did not play a required role in directly regu-
lating proteolytic activity and the measured KM values 
were not significantly different between WT- MT1- MMP 
and MT1- MMP(ΔCT) (Table 2). The enhanced activity of 
MT1- MMP(ΔCT) compared with WT- MT1- MMP may be 
the result of the internalization of the latter in a complex 
with substrates, reducing, as a result, the observed hydroly-
sis rate for the wild- type enzyme. In agreement with these 
findings, CT deletion has previously been shown to en-
hance the type I collagen- invasive potential of epithelial as 
well as mesenchymal cell populations (Jiang & Pei, 2003; 
Li et al., 2008; Sabeh et al., 2009). In addition, replacement 
of the CT and the TM domain of MT1- MMP with the gly-
cosylphosphatidylinositol anchor of MT6- MMP enhanced 
MDCK cell invasion in a three- dimensional type I collagen 
matrix (Nie, Pei, Blumenthal, & Pei, 2007).
The MT1- MMP HPX domain has been reported to play 
critical roles in a range of functions, including the forma-
tion of MT1- MMP homodimers, MT1- MMP•CD44 and 
MT1- MMP•tetraspanin heterodimerization, and MT1- 
MMP•type I collagen- binding interactions (D’ortho et al., 
1997; Mori et al., 2002; Murphy & Nagase, 2011; Tam 
et al., 2004; Tochowicz et al., 2011; Yañez- Mó et al., 2008; 
Zarrabi et al., 2011). However, deletion of the HPX domain 
only slightly reduced the kcat/KM value of the mutant en-
zyme relative to WT- MT1- MMP (Table 2). The reduction 
was entirely due to an increased KM value. In solution, de-
letion of the HPX domain only reduced MT1- MMP activity 
toward the triple- helical substrate fTHP- 15- to 3.5- fold (i.e., 
kcat/KM = 26,700 M−1 s−1 for soluble MT1- MMP versus 
7,660 M−1 s−1 for soluble MT1- MMP(ΔHPX)) (Zhao et al., 
2015). Interestingly, despite changes in catalytic activity, 
these results are consistent with previous studies demonstrat-
ing the ability of MT1- MMP(ΔHPX) to support collageno-
lytic and tissue- invasive activities when expressed in COS 
cells or fibroblasts (Li et al., 2008; Sabeh et al., 2009). Thus, 
our data support the contention that the triple- helicase and 
collagen- binding activities of the HPX domain play con-
tributory, but not absolute, roles for MT1- MMP function in 
intact cell systems (Li et al., 2008). Most likely, the HPX 
domain serves as a “modulator” of the CAT domain by en-
hancing activity through coupled motions (as discussed ear-
lier) and/or dampening activity of hyperactive CAT domains 
(Gioia et al., 2002). Additional support for this latter notion 
is provided by the observation that the MT1- MMP CAT do-
main alone exhibits a 5.0- to 7.5- fold higher catalytic activity 
toward single- stranded synthetic substrates compared with 
the soluble full- length enzyme (Hurst et al., 2004; Neumann, 
Kubota, Frei, Ganu, & Leppert, 2004).
In our efforts to identify potentially unique properties as-
sociated with the MT1- MMP CAT domain, we replaced the 
wild- type CAT domain with that of secreted interstitial colla-
genase, MMP- 1. MT1- MMP(MMP- 1 CAT) had a ~4.2- fold 
reduced activity compared with WT- MT1- MMP (Table 2). 
This reduction was a result of both an increased KM value 
and a decreased kcat value. As previously reported, solu-
ble MMP- 1 had reduced activity toward fTHP- 9 compared 
with soluble MT1- MMP (Minond et al., 2006). The magni-
tude of the difference was greater for the soluble enzymes, 
but the comparison is not straightforward, as the mutant we 
used included the MT1- MMP HPX domain (while the sol-
uble MMP- 1 has its native HPX domain). Though the col-
lagenolytic activity of MT1- MMP(MMP- 1 CAT) is about a 
half of that of WT- MT1- MMP (Li et al., 2008), this result 
is consistent with previous studies demonstrating that the 
collagen- invasive activity of fibroblasts, though retained to a 
significant degree, was decreased when the MMP- 1 CAT do-
main was substituted for the MT1- MMP CAT domain (Sabeh 
et al., 2009).
Contributions from secondary binding sites within the 
MT1- MMP CAT domain and/or other cell surface biomole-
cules (such as integrins) may also promote MT1- MMP col-
lagenolysis (Fields, 2013; Rowe & Weiss, 2009). The need 
for proper interaction of MT1- MMP with cell surface part-
ners is suggested by a recent study of the 163–170 loop re-
gion within MT1- MMP CAT domain. This MT (membrane 
type)- loop region is present in the CAT domain of MT1- 
MT6- MMPs, but is absent in all other MMPs. Deletion of 
this loop has been reported to result in the mis- localization of 
MT1- MMP relative to β1 integrin adhesion complexes with 
subsequent decreases in collagenolytic activity (Woskowicz, 
Weaver, Shitomi, Ito, & Itoh, 2013). However, these results 
stand in contrast with earlier reports that the MT- loop region 
does not play a required role in MT1- MMP- dependent col-
lagenolysis (Li et al., 2008) and further studies are required 
to resolve these discrepancies.
Finally, the present approach allowed for the evaluation 
of the effectiveness of proteinase inhibitors at the cell sur-
face. Both small molecule and mini- protein inhibitors were 
found to be active toward cell surface triple- helical pepti-
dase activity, albeit with reduced efficiency compared with 
inhibition in solution. The inhibition of MMP cell surface 
activity has been quantified previously using fluorescein- 
conjugated gelatin (Diehl et al., 2011). However, gelatin 
is a substrate for multiple proteases, and MMPs were ex-
pressed on the surface of yeast cells (Diehl et al., 2011), 
which are quite different from mammalian cell surfaces. 
As several selective and/or secondary binding site (exosite) 
MT1- MMP inhibitors have been described (Levin, Udi, 
Solomonov, & Sagi, 2017; Ling et al., 2017; Pahwa et al., 
2014; Santamaria & de Groot, 2018), the evaluation of 
activity at the cell surface will allow for examination of 
such inhibitors in a more native- like environment. This will 
also facilitate the development of inhibitors that may act 
indirectly on MT1- MMP activity. For example, MT1- MMP 
activity has been reported to be enhanced by tetraspanins 
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(Lafleur, Xu, & Hemler, 2009; Yañez- Mó et al., 2008) 
and bilayer membranes (Cerofolini et al., 2016; Marcink 
et al., 2018), and thus inhibitors may be designed to mit-
igate those interactions. MT1- MMP inhibitors have been 
described that disrupt the association of the enzyme with 
β integrin subunits on the cell surface (Woskowicz et al., 
2013; Yosef, Arkadash, & Papo, 2018).
The present cell- based assay could potentially be improved 
by creating a cell surface-bound substrate. To achieve this 
goal, lipid- like alkyl chains can be attached to the N- terminus 
of the MT1- MMP substrate fTHP- 9. We have previously used 
this approach to stabilize fTHPs (Lauer- Fields, Sritharan, 
Stack, Nagase, & Fields, 2003; Minond et al., 2004, 2006). 
An MMP- 12 FRET substrate has been anchored to the cell 
surface via palmitoylation (Cobos- Correa, Trojanek, Diemer, 
Mall, & Schultz, 2009). The previously discussed ECFP/
Ypet, mOrange2/mCherry, and ECFP- PEbody/R- PE MT1- 
MMP biosensors all incorporated the transmembrane domain 
of platelet- derived growth factor receptor to promote cell sur-
face anchoring (Limsakul et al., 2018; Ouyang et al., 2008, 
2010). Quasi- irreversible insertion into membranes can also 
be achieved via peptide modification by cholesterol, whereby 
cholesteryl chloroformate or cholest- 5- en- 3- yl bromoacetate 
is used to attach cholesterol to the N- terminus of the peptide 
or the side chain of a Cys residue, respectively (Ingallinella 
et al., 2009; Li et al., 2013). With a surface-bound substrate, 
one can minimize diffusion effects and increase the local en-
zyme•substrate concentration. A potential drawback is that 
the surface-bound substrate might disrupt interactions be-
tween the enzyme and native cell surface binding partners 
(see above). Future studies can be designed to evaluate sol-
uble versus cell surface-bound substrates in the MT1- MMP 
cell- based assay described herein.
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